Gemcitabine alters the proteasome composition and immunopeptidome of tumour cells
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Gemcitabine alters the proteasome composition and immunopeptidome of tumour cells
Authors
Keywords
-
Journal
OncoImmunology
Volume 7, Issue 6, Pages e1438107
Publisher
Informa UK Limited
Online
2018-02-09
DOI
10.1080/2162402x.2018.1438107
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The urgent need to recover MHC class I in cancers for effective immunotherapy
- (2016) Federico Garrido et al. CURRENT OPINION IN IMMUNOLOGY
- Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
- (2016) Jesse M. Zaretsky et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase I pilot study of Wilms tumor gene 1 peptide-pulsed dendritic cell vaccination combined with gemcitabine in pancreatic cancer
- (2015) Shuhei Mayanagi et al. CANCER SCIENCE
- Combined analysis of HLA class I, HLA-E and HLA-G predicts prognosis in colon cancer patients
- (2013) E C M Zeestraten et al. BRITISH JOURNAL OF CANCER
- The effects of gemcitabine and capecitabine combination chemotherapy and of low-dose adjuvant GM-CSF on the levels of myeloid-derived suppressor cells in patients with advanced pancreatic cancer
- (2013) Nicola E. Annels et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Dendritic cell immunotherapy combined with gemcitabine chemotherapy enhances survival in a murine model of pancreatic carcinoma
- (2013) Tomar Ghansah et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Immune escape of cancer cells with beta2-microglobulin loss over the course of metastatic melanoma
- (2013) Ana B. del Campo et al. INTERNATIONAL JOURNAL OF CANCER
- HLA Peptide Length Preferences Control CD8+ T Cell Responses
- (2013) M. J. Rist et al. JOURNAL OF IMMUNOLOGY
- Properties of MHC Class I Presented Peptides That Enhance Immunogenicity
- (2013) Jorg J. A. Calis et al. PLoS Computational Biology
- Chemotherapy broadens the range of tumor antigens seen by cytotoxic CD8+ T cells in vivo
- (2012) Connie Jackaman et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Implication of the β2-microglobulin gene in the generation of tumor escape phenotypes
- (2012) Monica Bernal et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Chemotherapeutics and Radiation Stimulate MHC Class I Expression through Elevated Interferon-beta Signaling in Breast Cancer Cells
- (2012) Shan Wan et al. PLoS One
- Clinical implication of HLA class I expression in breast cancer
- (2011) Koichi Kaneko et al. BMC CANCER
- The role of the proteasome in the generation of MHC class I ligands and immune responses
- (2011) E. J. A. M. Sijts et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- Proteasome subtypes and the processing of tumor antigens: increasing antigenic diversity
- (2011) Nathalie Vigneron et al. CURRENT OPINION IN IMMUNOLOGY
- Clinical and Immunologic Evaluation of Dendritic Cell–Based Immunotherapy in Combination With Gemcitabine and/or S-1 in Patients With Advanced Pancreatic Carcinoma
- (2011) Yukino Kimura et al. PANCREAS
- Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responses
- (2009) W M Liu et al. BRITISH JOURNAL OF CANCER
- Association of HLA class I antigen abnormalities with disease progression and early recurrence in prostate cancer
- (2009) Barbara Seliger et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Gemcitabine directly inhibits myeloid derived suppressor cells in BALB/c mice bearing 4T1 mammary carcinoma and augments expansion of T cells from tumor-bearing mice
- (2009) Hanh K. Le et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Regular Dose of Gemcitabine Induces an Increase in CD14+ Monocytes and CD11c+ Dendritic Cells in Patients with Advanced Pancreatic Cancer
- (2009) Atsuko Soeda et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- A Combination Therapy of Gemcitabine With Immunotherapy for Patients With Inoperable Locally Advanced Pancreatic Cancer
- (2009) Yoshiki Hirooka et al. PANCREAS
- Pretreatment with Cisplatin Enhances E7-Specific CD8+ T-Cell-Mediated Antitumor Immunity Induced by DNA Vaccination
- (2008) C.-W. Tseng et al. CLINICAL CANCER RESEARCH
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started